Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 119,805 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares in the company, valued at $1,498,675.08. The trade was a 3.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total value of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Trading Up 4.0 %

Shares of NASDAQ:IVVD opened at $0.53 on Friday. Invivyd, Inc. has a 52 week low of $0.40 and a 52 week high of $5.20. The firm has a market capitalization of $63.44 million, a P/E ratio of -0.27 and a beta of 0.53. The firm’s 50 day moving average is $0.74 and its two-hundred day moving average is $0.99.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Proficio Capital Partners LLC bought a new stake in shares of Invivyd during the 3rd quarter worth about $27,000. XTX Topco Ltd raised its stake in shares of Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after buying an additional 15,376 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after buying an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. bought a new position in Invivyd during the second quarter valued at about $86,000. Finally, Rhumbline Advisers raised its position in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IVVD has been the topic of several analyst reports. Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. HC Wainwright cut their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.